| abstract |
The present application provides compounds useful, for example, in performing the following: inhibiting the formation of an endothelin pore in a cell; inhibition of inflammatory corpuscle-mediated cell death (apoptosis); inhibiting cytokine secretion from the cell; inhibit inflammatory caspases in the cell and/or covalently react with cysteines of the endothelin protein in the cell. These compounds are also useful for treating or preventing diseases or conditions in which inflammasome activation is implicated in pathogenesis. One example of such a disease or condition is sepsis. |